81 results
Page 2 of 5
8-K
EX-99.1
pqog9gr
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
8-K
EX-99.1
cvfzw29 nh2i2t4dtl
4 Nov 22
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:22am
424B5
1ieh6703obcjlx0
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
ucp7e 1sh5rh5znn8
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
EX-99.1
77c42ni
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.2
u2vvh
13 Sep 22
Regulation FD Disclosure
9:07am
8-K
EX-99.1
a0s uru1ff
4 Aug 22
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
4:17pm
8-K
EX-99.1
lj8m44
8 Jun 22
Regulation FD Disclosure
9:06am
8-K
EX-99.1
zzqa7 wx9invzfed5x
25 Feb 22
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
7:15am
8-K
EX-99.1
b4h j9fupi
9 Sep 21
A Global Disease, A Pioneering Treatment Corporate Presentation September 2021
4:46pm
8-K
EX-99.1
p66s blmx4sapp
13 Aug 21
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
7:04am
8-K
EX-99.1
voeghy gbq6
25 Jun 21
Regulation FD Disclosure
4:51pm
8-K
EX-99.1
fsnw8zqgi
21 Jun 21
Regulation FD Disclosure
8:15am